Statin therapy for coronary heart disease and its effect on stroke

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Coronary heart disease (CHD) and stroke share common risk factors and are the leading causes of death and disability in the United States. Although the impact of elevated cholesterol on stroke risk has been disputed, numerous trials using 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (ie, statins) in patients with CHD have demonstrated a significant reduction in stroke incidence as a secondary endpoint. It is likely that statins are pleiotropic in stroke prevention, providing benefits through both cholesterol reduction and cholesterol-independent mechanisms. In this article, we review the relationship between cholesterol and stroke, randomized trials of statins in patients with CHD and high risk for CHD that have assessed stroke risk, and the putative mechanisms of stroke prevention by statins.

Original languageEnglish (US)
Pages (from-to)337-342
Number of pages6
JournalCurrent Atherosclerosis Reports
Volume8
Issue number4
DOIs
StatePublished - Jul 1 2006

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Coronary Disease
Stroke
Cholesterol
Therapeutics
Hypercholesterolemia
Cause of Death
Oxidoreductases
Incidence

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Statin therapy for coronary heart disease and its effect on stroke. / Switzer, Jeffrey A; Hess, David C.

In: Current Atherosclerosis Reports, Vol. 8, No. 4, 01.07.2006, p. 337-342.

Research output: Contribution to journalReview article

@article{69528be5264e4b26a0d76a466602bd68,
title = "Statin therapy for coronary heart disease and its effect on stroke",
abstract = "Coronary heart disease (CHD) and stroke share common risk factors and are the leading causes of death and disability in the United States. Although the impact of elevated cholesterol on stroke risk has been disputed, numerous trials using 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (ie, statins) in patients with CHD have demonstrated a significant reduction in stroke incidence as a secondary endpoint. It is likely that statins are pleiotropic in stroke prevention, providing benefits through both cholesterol reduction and cholesterol-independent mechanisms. In this article, we review the relationship between cholesterol and stroke, randomized trials of statins in patients with CHD and high risk for CHD that have assessed stroke risk, and the putative mechanisms of stroke prevention by statins.",
author = "Switzer, {Jeffrey A} and Hess, {David C}",
year = "2006",
month = "7",
day = "1",
doi = "10.1007/s11883-006-0013-0",
language = "English (US)",
volume = "8",
pages = "337--342",
journal = "Current Atherosclerosis Reports",
issn = "1523-3804",
publisher = "Current Medicine Group",
number = "4",

}

TY - JOUR

T1 - Statin therapy for coronary heart disease and its effect on stroke

AU - Switzer, Jeffrey A

AU - Hess, David C

PY - 2006/7/1

Y1 - 2006/7/1

N2 - Coronary heart disease (CHD) and stroke share common risk factors and are the leading causes of death and disability in the United States. Although the impact of elevated cholesterol on stroke risk has been disputed, numerous trials using 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (ie, statins) in patients with CHD have demonstrated a significant reduction in stroke incidence as a secondary endpoint. It is likely that statins are pleiotropic in stroke prevention, providing benefits through both cholesterol reduction and cholesterol-independent mechanisms. In this article, we review the relationship between cholesterol and stroke, randomized trials of statins in patients with CHD and high risk for CHD that have assessed stroke risk, and the putative mechanisms of stroke prevention by statins.

AB - Coronary heart disease (CHD) and stroke share common risk factors and are the leading causes of death and disability in the United States. Although the impact of elevated cholesterol on stroke risk has been disputed, numerous trials using 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (ie, statins) in patients with CHD have demonstrated a significant reduction in stroke incidence as a secondary endpoint. It is likely that statins are pleiotropic in stroke prevention, providing benefits through both cholesterol reduction and cholesterol-independent mechanisms. In this article, we review the relationship between cholesterol and stroke, randomized trials of statins in patients with CHD and high risk for CHD that have assessed stroke risk, and the putative mechanisms of stroke prevention by statins.

UR - http://www.scopus.com/inward/record.url?scp=33745919797&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745919797&partnerID=8YFLogxK

U2 - 10.1007/s11883-006-0013-0

DO - 10.1007/s11883-006-0013-0

M3 - Review article

VL - 8

SP - 337

EP - 342

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

SN - 1523-3804

IS - 4

ER -